Physician profile
Mark Duca
NPI 1023081445
$483.43
in general payments reported to CMS, 2019-2025
9 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.66 · 2020: $17.73 · 2021: $14.94 · 2023: $66.40 · 2024: $196 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $239.61 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $63.29 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $45.52 | 2024-2025 | Eliquis |
| Exact Sciences Corporation | $43.58 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $24.88 | 2024 | Wegovy |
| Lilly USA, LLC | $21.07 | 2025 | Zepbound, Mounjaro |
| Genentech USA, INC. | $15.66 | 2019 | |
| Abbott Laboratories | $14.94 | 2021 | |
| Dexcom, INC. | $14.88 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Duca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.